PT  - JOURNAL ARTICLE
AU  - Diane K. Soulek
AU  - Molly E. Martin
AU  - Nic J. Mastascusa
AU  - Stephen A. Graves
TI  - Practical Considerations for Implementation of <sup>177</sup>Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
AID  - 10.2967/jnmt.122.263813
DP  - 2022 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - 195--202
VI  - 50
IP  - 3
4099  - http://tech.snmjournals.org/content/50/3/195.short
4100  - http://tech.snmjournals.org/content/50/3/195.full
SO  - J. Nucl. Med. Technol.2022 Sep 01; 50
AB  - The 2018 Food and Drug Administration approval of 177Lu-DOTATATE for the treatment of somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm-shifting approach to cancer treatments around the globe. Gastroenteropancreatic NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent Food and Drug Administration approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy, 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals; 177Lu-DOTATATE patient selection criteria; administration methods; clinical, regulatory, and radiation safety considerations; technical factors; tissue dosimetry; and reimbursement guidelines.